Literature DB >> 15102006

Is laboratory monitoring of low-molecular-weight heparin therapy necessary? Yes.

J Harenberg1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15102006     DOI： 10.1111/j.1538-7933.2004.00647.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  11 in total

1.  Anti-Xa Levels 4 h After Subcutaneous Administration of 5,700 IU Nadroparin Strongly Correlate with Lean Body Weight in Morbidly Obese Patients.

Authors:  Jeroen Diepstraten; Christian M Hackeng; Simone van Kralingen; Jiri Zapletal; Eric P A van Dongen; René J Wiezer; Bert van Ramshorst; Catherijne A J Knibbe
Journal:  Obes Surg       Date:  2012-02-01       Impact factor: 4.129

2.  Pulmonary embolism: current treatment options.

Authors:  Marc Meysman; Patrick Haentjens
Journal:  Curr Treat Options Cardiovasc Med       Date:  2005-12

Review 3.  Optimizing the use of anticoagulants (heparins and oral anticoagulants) in the elderly.

Authors:  Virginie Siguret; Isabelle Gouin-Thibault; Pascale Gaussem; Eric Pautas
Journal:  Drugs Aging       Date:  2013-09       Impact factor: 3.923

Review 4.  Prevention of venous thromboembolism in obesity.

Authors:  Andrew L Freeman; Robert C Pendleton; Matthew T Rondina
Journal:  Expert Rev Cardiovasc Ther       Date:  2010-12

5.  Population pharmacodynamic model for low molecular weight heparin nadroparin in morbidly obese and non-obese patients using anti-Xa levels as endpoint.

Authors:  Jeroen Diepstraten; Esther J H Janssen; Christian M Hackeng; Eric P A van Dongen; René J Wiezer; Bert van Ramshorst; Catherijne A J Knibbe
Journal:  Eur J Clin Pharmacol       Date:  2014-10-12       Impact factor: 2.953

6.  Adjustment of therapeutic LMWH to achieve specific target anti-FXa activity does not affect outcomes in pregnant patients with venous thromboembolism.

Authors:  Brendan P McDonnell; Kate Glennon; Aoife McTiernan; Hugh D O'Connor; Colin Kirkham; Barry Kevane; Jennifer C Donnelly; Fionnuala Ni Áinle
Journal:  J Thromb Thrombolysis       Date:  2017-01       Impact factor: 2.300

Review 7.  Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays.

Authors:  Jonathan Douxfils; Anne Tamigniau; Bernard Chatelain; Catherine Goffinet; Jean-Michel Dogné; François Mullier
Journal:  Thromb J       Date:  2014-11-04

Review 8.  The Anti-Factor Xa Range For Low Molecular Weight Heparin Thromboprophylaxis.

Authors:  Matthew Y Wei; Salena M Ward
Journal:  Hematol Rep       Date:  2015-11-23

Review 9.  Anticoagulant Treatment of Deep Vein Thrombosis and Pulmonary Embolism: The Present State of the Art.

Authors:  Johannes Thaler; Ingrid Pabinger; Cihan Ay
Journal:  Front Cardiovasc Med       Date:  2015-07-14

10.  Reduced dosing of enoxaparin for venous thromboembolism in overweight and obese adolescents: a single institution retrospective review.

Authors:  Stephanie Hoffman; Chi Braunreiter
Journal:  Res Pract Thromb Haemost       Date:  2017-08-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.